Repare Therapeutics (NASDAQ:RPTX) Announces Earnings Results

Repare Therapeutics (NASDAQ:RPTX) released its earnings results on Monday. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.10, Zacks reports. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%.

Repare Therapeutics Price Performance

Shares of NASDAQ RPTX traded up $0.05 during midday trading on Wednesday, hitting $1.22. 2,839 shares of the company’s stock were exchanged, compared to its average volume of 293,664. The company has a market cap of $51.65 million, a PE ratio of -0.61 and a beta of 0.87. Repare Therapeutics has a twelve month low of $1.06 and a twelve month high of $6.73. The firm’s fifty day simple moving average is $1.26 and its 200-day simple moving average is $2.45.

Analyst Upgrades and Downgrades

RPTX has been the subject of a number of research analyst reports. Stifel Nicolaus cut their price target on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a report on Friday, December 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a report on Friday, November 8th. Lifesci Capital restated a “market perform” rating on shares of Repare Therapeutics in a research note on Friday, December 13th. Finally, Bloom Burton downgraded Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 10th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.